Table 2

PRO measures in the ITT patient group (paired samples)

16 weeks8 months12 months
ACT scoren=222n=177n=187
 Mean (SD) at baseline9.76 (4.29)9.77 (4.38)9.84 (4.34)
 Mean (SD) at visit15.01 (5.71)14.99 (5.78)14.41 (5.69)
 Mean difference (95% CI)5.26 (4.58 to 5.93)*5.22 (4.43 to 6.00)*4.57 (3.75 to 5.38)*
AQLQ scoren=192n=149n=161
 Mean (SD) at baseline3.27 (1.29)3.14 (1.28)3.20 (1.27)
 Mean (SD) at visit4.65 (1.55)4.61 (1.54)4.39 (1.48)
 Mean difference (95% CI)1.38 (1.18 to 1.58)*1.47 (1.25 to 1.70)*1.20 (0.97 to 1.42)*
EQ-5D indexn=215n=167n=173
 Mean (SD) at baseline0.59 (0.25)0.58 (0.26)0.58 (0.25)
 Mean (SD) at visit0.71 (0.25)0.68 (0.26)0.69 (0.26)
 Mean difference (95% CI)0.12 (0.09 to 0.15)*0.10 (0.06 to 0.13)*0.11 (0.08 to 0.15)*
EQ-5D VASn=196n=162n=166
 Mean (SD) at baseline54.2 (20.3)53.5 (20.3)54.3 (20.1)
 Mean (SD) at visit66.8 (21.2)67.1 (21.9)67.1 (20.9)
 Mean difference (95% CI)12.5 (9.5 to 15.5)*13.6 (10.3 to 17.0)*12.8 (9.4 to 16.2)*
  • *p<0.001.

  • ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; EQ:5D VAS, EuroQol five-dimensions visual analogue scale; ITT, intention to treat; PRO, patient-reported outcome.